Ribogenics is developing small molecule RNA-medicines to treat cancer, neurological disorders and rare diseases. Their platform is based on over 30 years of research in RNA splicing and RNA binding proteins from Dr. Dreyfuss’ lab at UPenn with proof-of-concept from Merck in rare disease. The Ribogenics Platform generates small molecule drug candidates that can correct the function, presence or absence of proteins enabling cells to operate normally with a validated high-throughput phenotypic screening platform that brings compounds from discovery to optimization to build a proprietary pipeline of drug candidates and partner with Pharma.